IXI Ixico Plc

TIDMIXI

RNS Number : 6717U

IXICO plc

27 November 2023

27 November 2023

IXICO plc

("IXICO" or the "Company")

Notice of Results and Investor Presentation

IXICO PLC (AIM: IXI), the medical imaging advanced analysis company delivering intelligent insights in neuroscience, confirms that it will issue its Full Year Results for the year to 30 September 2023 on Tuesday 5 December 2023.

Giulio Cerroni (CEO), Grant Nash (CFO) and Robin Wolz (CSO) will provide a live presentation relating to their Full Year Results via the Investor Meet Company platform on 5 December 2023 at 4:30pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor

Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited

For further information please contact:

 
 IXICO plc 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer                     +44 (0)20 3763 7499 
 
 C avendish Securities PLC (Nominated 
  adviser and sole broker)                                +44 (0)20 7220 0500 
 Giles Balleny / Dan Hodkinson (Corporate 
  Finance) 
  Charlie Combe (ECM) 
 Michael F Johnson / Tamar Cranford-Smith 
  (Sales) 
 
 
 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients .

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORNKABBFBDDDDB

(END) Dow Jones Newswires

November 27, 2023 02:00 ET (07:00 GMT)

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024